Get the Stockscreener App
213.76
2.08%
4.35
After Hours:
214.12
0.36
+0.17%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $213.76, with a volume of 7.22M.
It is up +2.08% in the last 24 hours and up +2.58% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$209.41
Open:
$209.9
24h Volume:
7.22M
Relative Volume:
1.08
Market Cap:
$377.67B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
105.44
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+2.84%
1M Performance:
+2.58%
6M Performance:
-8.22%
1Y Performance:
+15.10%
1-Day Range:
$208.73
$215.80
1-Week Range:
$204.30
$215.80
52-Week Range:
$180.25
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
213.76 | 369.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,021.41 | 881.12B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.00 | 551.06B | 96.36B | 21.04B | 17.80B | 8.6488 |
NVS
Novartis Ag Adr
|
150.44 | 284.59B | 54.66B | 13.58B | 16.05B | 7.0171 |
AZN
Astrazeneca Plc
|
184.64 | 285.23B | 60.48B | 10.40B | 8.05B | 3.3297 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
UCB (UCBJY) Reports Bimzelx Success Over AbbVie's Skyrizi in Pso - GuruFocus
Top 12 Undervalued Dividend Stocks to Buy Now - Insider Monkey
UCB says Bimzelx beat AbbVie’s Skyrizi in psoriatic arthritis trial - Seeking Alpha
AbbVie (ABBV) Price Target Lowered to $235 at Evercore ISI - Insider Monkey
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - Yahoo! Finance Canada
2 Reasons to Like ABBV and 1 to Stay Skeptical - Yahoo Finance
Neurotoxin Will Generate Booming Growth Opportunities to 2028 | AbbVie, Ipsen Group, Hugel, Inc., Medytox, Inc. etc. - openPR.com
AbbVie stock (US00287Y1091): Q1 2026 earnings highlight Skyrizi and Rinvoq as growth engines - AD HOC NEWS
AbbVie Inc stock (US00287Y1091): new oncology data and pipeline updates keep focus on long-term grow - AD HOC NEWS
Ill. Panel Sides With AbbVie In Eye-Stent Injury Suit - Law360
Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth - TradingView
TD Private Client Wealth LLC Sells 9,822 Shares of AbbVie Inc. $ABBV - MarketBeat
Mission Wealth Management LP Lowers Holdings in AbbVie Inc. $ABBV - MarketBeat
60,762 Shares in AbbVie Inc. $ABBV Acquired by North Dakota State Investment Board - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC - MarketBeat
AbbVie Inc. (ABBV) Stock Analysis: Unveiling a 20% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
AbbVie stock (US00287Y1091): focus on Humira erosion and Skyrizi growth after latest quarterly repor - AD HOC NEWS
AbbVie Inc stock (US00287Y1091): arthritis drug data and dividend keep the spotlight on the pharma g - AD HOC NEWS
AbbVie Inc. $ABBV Shares Sold by WealthPlan Investment Management LLC - MarketBeat
Soltis Investment Advisors LLC Acquires 12,096 Shares of AbbVie Inc. $ABBV - MarketBeat
L & S Advisors Inc Has $8.01 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Millennium Capital Advisors LLC Purchases New Shares in AbbVie Inc. $ABBV - MarketBeat
Abacus Wealth Partners LLC Boosts Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc stock (US00287Y1091): earnings momentum and pipeline keep big pharma name in focus - AD HOC NEWS
Lawood & Co. Takes Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Lockheed Martin Investment Management Co. - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Convergence Investment Partners LLC Has $4.58 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Commerzbank Aktiengesellschaft FI Sells 10,690 Shares of AbbVie Inc. $ABBV - MarketBeat
DNB Asset Management AS Acquires 81,312 Shares of AbbVie Inc. $ABBV - MarketBeat
Applied Finance Capital Management LLC Has $6.83 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Goldman Sachs Large Cap Growth Insights Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Inc. stock (US00287Y1091): Pipeline, Humira transition and US market exposure - AD HOC NEWS
ABBV Maintains Rating by Evercore ISI Group -- Price Target Lowe - GuruFocus
Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie? - The Globe and Mail
AbbVie stock (US00287Y1091): earnings beat and dividend keep focus on pipeline - AD HOC NEWS
How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results? - The Globe and Mail
Mubadala Investment Co Pjsc Raises Share Stake In Abbvie, Match Group,Cuts In CVS Health - TradingView
AbbVie Stock Is Up 22% Over the Past Year. Analysts See 37% Upside to $289 Target - TIKR.com
AbbVie FY2027 EPS Forecast Boosted by Erste Group Bank - MarketBeat
We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings - simplywall.st
AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
Evercore ISI Adjusts Price Target on AbbVie to $235 From $236, Maintains Outperform Rating - marketscreener.com
AbbVie Inc. $ABBV Shares Purchased by Phoenix Financial Ltd. - MarketBeat
Conning Inc. Has $35.85 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc (ABBV) Stock Price, Trades & News - GuruFocus
FDA Approval Gives BeOne Medicines a New Challenger to AbbVie, Roche Cancer Drug - MedCity News
BeiGene Must Face AbbVie's Chemical Trade Secret Claims - Law360
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Jim Cramer Reveals AbbVie’s (ABBV) “Good Stuff” - Insider Monkey
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):